Unlock instant, AI-driven research and patent intelligence for your innovation.

Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule

A technology of chimeric antigen receptors and macrophages, which can be used to target specific cell fusion, anti-receptor/cell surface antigen/cell surface determinant immunoglobulin, and use vectors to introduce foreign genetic material. Solve problems such as difficulty in meeting efficacy targets, side effects, poor immunogenicity, etc.

Pending Publication Date: 2019-09-20
NOVARTIS AG +1
View PDF251 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Many patients with malignancies are incurable with standard therapies
Additionally, traditional treatment options often have severe side effects
Attempts have been made in cancer immunotherapy, however, several obstacles make it difficult to achieve clinical effectiveness goals
Although hundreds of so-called tumor antigens have been identified, these are often self-derived and thus poorly immunogenic

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
  • Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
  • Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule

Examples

Experimental program
Comparison scheme
Effect test

example

[1158] The present invention is described in further detail by referring to the following experimental examples. These examples are provided for illustrative purposes only and should not be intended to be limiting unless otherwise stated. Therefore, the present invention should never be construed as being limited to the following examples, but should be construed as covering any and all changes that become apparent due to the teaching provided herein.

[1159] Without further description, it is believed that those of ordinary skill in the art can use the foregoing description and the following illustrative examples to prepare and utilize the compounds of the present invention and practice the claimed methods. The following working examples specifically point out different aspects of the present invention and should not be construed as limiting the rest of the disclosure in any way.

example 1

[1160] Example 1: Using chimeric antigen receptor T cells to overcome the immunosuppressive tumor microenvironment of Hodgkin’s lymphoma

[1161] Despite modern treatment options, a subset of patients with Hodgkin's lymphoma (HL) is still subject to this disease. Specifically, 10%-15% of patients initially suffering from local disease and 20%-40% of patients initially suffering from advanced disease will eventually relapse. Josting A, Franklin J, May M, Koch P, Beykirch MK, Heinz J, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin'slymphoma study group [Based on New predictive scores for the treatment outcome of patients with recurrent Hodgkin’s lymphoma registered in the Golden Lymphoma Research Group database]. Am J Clin Oncol. [American Journal of Clinical Oncology] 2002; 20:221-30. In addition, 10%-15% of patients suffer from diseases that are refractory to first-line treatmen...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides compositions and methods for treating diseases associated with expression of an antigen, e.g., a solid tumor antigen or antigen expressed on a tumor associated with TAMs and / or MDSCs, by administering a recombinant T cell comprising a CAR binding to said antigen, as described herein, in combination with an inhibitor of a pro-M2 macrophage molecule, e.g., described herein. The invention also provides kits and compositions described herein.

Description

[0001] Related application [0002] This application claims the priority of US serial number 62 / 369589 filed on August 1, 2016, the content of which is incorporated herein by reference in its entirety. [0003] Sequence Listing [0004] This application contains a sequence listing that has been submitted electronically in ASCII format and the sequence listing is hereby incorporated by reference in its entirety. The ASCII copy was created on July 31, 2017, the name is N2067-7113WO_SL.txt and the size is 1,549,304 bytes. Technical field [0005] The present invention generally relates to T cells engineered to express chimeric antigen receptors (CAR), for example, in combination with another agent, such as a pro-M2 macrophage molecule (pro-M2 macrophage molecule) inhibitor, for treatment with cancer antigens (e.g., Use of solid tumor antigens or antigens on cancer cells related to tumor-associated macrophages) expression-related diseases, such as IL-13, IL-13Rα1, IL-4, IL-4Rα, IL-10 or ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/00C07K16/24C07K16/28
CPCC07K16/2803C07K16/2866C07K2319/33C07K2317/622C07K2319/02A61P35/00A61K39/4611A61K39/4631A61K39/464419A61K39/464404A61K2239/38A61K39/464412A61K2239/48A61K2239/13A61K2300/00A61K39/395A61K45/06C12N2740/15043A61K2039/585A61K2039/545A61K2039/5256C07K2317/565A61K35/17A61K39/001129A61K39/001112A61K39/001168A61K39/001104A61K2039/5158A61K2039/5156C07K16/24C07K16/28C12N15/86A61K39/0011
Inventor S·吉尔M·鲁艾拉M·克利辛基斯基
Owner NOVARTIS AG